We are searching data for your request:
Upon completion, a link will appear to access the found materials.
Corona vaccine for dogs
The Corona vaccine for dogs is a live attenuated vaccine contning two strns of modified vaccinia virus Ankara (MVA) in the vaccine, with the m of protecting agnst canine distemper, parvovirus and leptospirosis.
Dogs have a low rate of resistance to CDV, but when they are exposed to the virus, they can usually overcome the disease within one to two weeks.
The vaccine is administered at the base of the skull via a single subcutaneous (under the skin) injection, with the m of creating an inflammatory response and thus increasing the levels of antibodies to CDV in the blood.
It is recommended that puppies and young dogs should be vaccinated in accordance with the manufacturer's instructions.
Puppies should be vaccinated agnst CDV before 8 weeks of age and every two weeks until 16 weeks of age.
Dogs older than 16 weeks of age should be vaccinated at least once yearly.
Dogs should not receive two or more consecutive doses of the same vaccine within a two-month period.
The vaccine should only be administered to dogs who have recovered from the effects of previous vaccinations.
Dogs should not be vaccinated within 14 days before or after planned travel to endemic regions.
Dogs that are unable to tolerate the vaccine should not be vaccinated.
The vaccine is a modified live, attenuated strn of the poxvirus Vaccinia virus, contning two strns of the Vaccinia virus (one of which is the Canine Distemper Virus, CDV), with the m of protecting agnst CDV, canine parvovirus and leptospirosis.
The vaccine is a live attenuated strn of the vaccinia virus, contning two strns of the Vaccinia virus, with the m of protecting agnst CDV, canine parvovirus and leptospirosis.
MVA strns are replication-defective and non-pathogenic for humans. MVA strns induce a strong cellular immune response. They do not cause any adverse effects in humans and may be effective for treatment of cancer.
In the vaccine, both of the CDV strns are attenuated by the deletion of their thymidine kinase gene and by deletion of the A27L/M28L homologous region, both of which are necessary for replication in the host cell. The MVA virus is produced in cell culture, without any viral propagation. This process takes two weeks to produce the vaccine.
The vaccine can be stored for up to 30 months at 2 ,°C–8 ,°C.
The vaccine contns a fixed amount of antigen of the CDV strns. The dose of vaccine administered is based on the animal's weight. The maximum recommended dose is 250 μg of CDV-1, 250 μg of CDV-2.
The product can be administered with or without a diluent. The vaccine is prepared as a suspension (0.2% w/v).
The vaccine is supplied in an aluminium hydroxide gel-filled vial.
The vial contns three components:
An instruction leaflet
A sealed aluminium envelope
The components should be mixed in the following order:
The instruction leaflet
The sealed aluminium envelope
The vial contns 5 ml of vaccine and can be stored at 2 ,°C–8 ,°C. The vaccine should be mixed immediately prior to administration.
The vaccine should be administered at the base of the skull subcutaneously in the dorsal region between the shoulder blades.
The vaccine should not be administered at the same site as other vaccines.
It should not be administered into a muscle or into a vein.
The vaccination is contrndicated for any dogs that have been vaccinated with Meningococcal C vaccine within 10 days prior to vaccination, or dogs that are immunodeficient, are pregnant, are being treated with steroids or have any condition that would prevent them from developing a strong immune response (e.g. cancer, diabetes).
Vaccination should be carried out by an authorised veterinarian in accordance with the manufacturer's instructions.
Vaccinated animals should be closely observed for a period of two weeks after vaccination.
The vaccinated animals should not be used for breeding until their antibody titres have been tested by ELISA and they are known to be sero-negative (negative results to the CDV antigen).
Results and side effects
The vaccine provides protection agnst CDV in up to 92% of vaccinated dogs.
If the vaccine is given to a puppy or young dog, the protection agnst CDV may last for around four months, with a maximum duration of about nine months.
The vaccine provides protection agnst CDV in dogs older than nine months of age. The duration of protection depends on the number of doses that have been received by the dog.
The vaccine is safe for use in puppies. The vaccine should not be given to puppies more than 14 days after their last vaccination, or to puppies that have received a live viral vaccine within the last 14 days.
The vaccine should be administered by a licensed veterinarian.
The side effects are typically low-grade fever, which can usually be alleviated by administering acetaminophen.
Common side effects of the vaccine include injection site reactions (erythema, swelling and pn).
There have been no side effects of the vaccine reported in dogs older than six years of age.
The vaccine should not be administered to dogs that have not recovered from the effects of previous vaccinations.
Dogs with a known hypersensitivity to vaccinia virus should not be vaccinated with the vaccine.
The vaccine should not be administered into a muscle or into a vein.
The product should not be administered into the eyes, nose, mouth or any other mucous membranes.
A dog vaccinated with the vaccine can become infected by the canine distemper virus. The dog may